Jinxin Fertility launches HK IPO for $381m

By Jonathan Breen
11 Jun 2019

Chinese healthcare company Jinxin Fertility Group has kicked off a week-long roadshow for its Hong Kong IPO, looking to raise up to HK$2.99bn ($381.4m) from the deal, said a source close to the situation.

Jinxin provides assisted reproductive services (ARS), which include for example, in vitro fertilisation (IVF) treatments. It has businesses in China and the US.

The company is working with sponsors CLSA and Morgan Stanley to run its IPO. The team is marketing a float of 350m shares at a ...

Already a subscriber?

Continue reading this article

Try full access to GlobalCapital

Free trial